MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/82.5/0.1/20.12.24 | Real-time Bid/Ask 08:47:42 2024-06-24 EDT | ||
| 0.199 EUR / 0.209 EUR | +9.09% |
|
| Current month | +240.00% | ||
| 1 month | +105.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 0.198 | +5.88% |
| 24-06-21 | 0.187 | +37.50% |
| 24-06-20 | 0.136 | +134.48% |
| 24-06-19 | 0.058 | -15.94% |
| 24-06-18 | 0.069 | -13.75% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 08:44 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MB331B |
| ISIN | DE000MB331B1 |
| Date issued | 2023-02-01 |
| Strike | 82.5 $ |
| Maturity | 2024-12-20 (179 Days) |
| Parity | 10 : 1 |
| Emission price | 1.46 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.54 € |
|---|---|
| Lowest since issue | 0.044 € |
| Spread | 0.009 € |
| Spread % | 4.43% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.89
USD
Spread / Average Target
+17.29%
- Stock Market
- Warrants
- Warrant
